A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era
SM Pfister, M Reyes-Múgica, JKC Chan, H Hasle… - Cancer discovery, 2022 - AACR
Pediatric tumors are uncommon, yet are the leading cause of cancer-related death in
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …
Tumour predisposition and cancer syndromes as models to study gene–environment interactions
Cell division and organismal development are exquisitely orchestrated and regulated
processes. The dysregulation of the molecular mechanisms underlying these processes …
processes. The dysregulation of the molecular mechanisms underlying these processes …
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
G Bougeard, M Renaux-Petel, JM Flaman… - Journal of Clinical …, 2015 - ascopubs.org
Purpose The aim of the study was to update the description of Li-Fraumeni syndrome (LFS),
a remarkable cancer predisposition characterized by extensive clinical heterogeneity …
a remarkable cancer predisposition characterized by extensive clinical heterogeneity …
Detection of germline variants in Brazilian breast cancer patients using multigene panel testing
RSC Guindalini, DV Viana, JPFW Kitajima… - Scientific reports, 2022 - nature.com
Genetic diversity of germline variants in breast cancer (BC) predisposition genes is
unexplored in miscegenated populations, such those living in Latin America. We evaluated …
unexplored in miscegenated populations, such those living in Latin America. We evaluated …
Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database
BACKGROUND: Sarcoma is the index diagnosis of Li‐Fraumeni syndrome (LFS), a familial
predisposition to cancer that also includes brain cancer, breast cancer, and adrenal cortical …
predisposition to cancer that also includes brain cancer, breast cancer, and adrenal cortical …
Impact of Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early Detection of Childhood Adrenocortical Tumors
G Custódio, GA Parise, N Kiesel Filho… - Journal of Clinical …, 2013 - ascopubs.org
Purpose The incidence of pediatric adrenocortical tumors (ACTs) is remarkably high in
southern Brazil, where more than 90% of patients carry the germline TP53 mutation R337H …
southern Brazil, where more than 90% of patients carry the germline TP53 mutation R337H …
Germline TP53 Mutations and the Changing Landscape of Li–Fraumeni Syndrome
J Kamihara, HQ Rana, JE Garber - Human mutation, 2014 - Wiley Online Library
Since its description by L i and F raumeni over 40 years ago, L i–F raumeni syndrome (LFS)
remains one of the most striking familial cancer predisposition syndromes. Children and …
remains one of the most striking familial cancer predisposition syndromes. Children and …
Ethical, social, and cultural issues related to clinical genetic testing and counseling in low-and middle-income countries: a systematic review
A Zhong, B Darren, B Loiseau, LQB He, T Chang… - Genetics in …, 2021 - nature.com
Purpose We performed a systematic review of the ethical, social, and cultural issues
associated with delivery of genetic services in low-and middle-income countries (LMICs) …
associated with delivery of genetic services in low-and middle-income countries (LMICs) …
Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect
S Garritano, F Gemignani, EI Palmero… - Human …, 2010 - Wiley Online Library
Due to patterns of migration, selection, and population expansion, founder effects are
common among humans. In Southern Brazil, a recurrent TP53 mutation, p. R337H, is …
common among humans. In Southern Brazil, a recurrent TP53 mutation, p. R337H, is …
Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome: Current Status of Clinical Applications and Future Directions
AD Sorrell, CR Espenschied, JO Culver… - Molecular diagnosis & …, 2013 - Springer
Prevalent as an acquired abnormality in cancer, the role of tumor protein p53 (TP53) as a
germline mutation continues to evolve. The clinical impact of a germline TP53 mutation is …
germline mutation continues to evolve. The clinical impact of a germline TP53 mutation is …